Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)"

Erstveröffentlichung

2018

Metadata only
Search for full text

Wissenschaftlicher Artikel

Authors

Kosiborod, Mikhail

Cavender, Matthew A.

Fu, Alex Z.

Wilding, John P.

Khunti, Kamlesh

et al.

Faculties

Medizinische Fakultät

Institutions

Institut für Epidemiologie und Medizinische Biometrie

Published in

Circulation ; 137 (2018), 9. - S. 989-991. - ISSN 0009-7322. - eISSN 1524-4539

Link to publication

https://dx.doi.org/10.1161/CIRCULATIONAHA.117.031847

Funding information

AstraZeneca
Boehringer Ingelheim
Merck
Sanofi-Aventis
Chiesi
etc.

Dewey Decimal Group

DDC 610 / Medicine & health

---

Metadata

Show full item record